About this trial
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD.
Participants will be asked to:
* Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.
Eligibility criteria
Qualifiers
Men and women
Age 18-75
BMI >25 kg/m2 OR waist circumference >94 cm (men) or 80cm (women)
Fasting serum glucose >100 mg/dL OR 2-hour post-prandial glucose levels >140mg/dL OR AbA1c >5.7% OR type 2 diabetes OR treatment for type 2 diabetes
Disqualifiers
Pregnancy or breast feeding
Premenopausal women not on any form of contraception
Reports alcohol intake >50g/day or 350g/week for women and >60g/day or 420g/week for men or an AUDIT score >8
Other identifiable causes of steatosis
Trial design
Treatments tested in this trial
- Tirzepatide
Treatment groups
Sponsors and collaborators
University of New Mexico
Lead sponsor
American Cancer Society, Inc.
Collaborator
University of New Mexico Cancer Center
Collaborator